BA
Bal Pharma Ltd (BALPHARMA)
₹106.79
Mkt cap
₹160 Cr
P/E ratio
22.30
P/B
2.07
Div yield
1.19%
ROE
7.87%
ROCE
9.69%
EPS (TTM)
₹4.79
Book value
₹52
52W range
60–125
Sector
Healthcare
Price history
Previous close
Incorporated in 1987, Bal Pharma Ltd does manufacturing and selling of pharmaceutical products and related services [1]
NSE BALPHARMABSE 524824
Health check
Mixed
ValuationCheap
ProfitabilityWeak
GrowthLow
TechnicalsBullish
52-week range
−14.29% from high₹107
₹60+77.98% from low₹125
Current
₹106.79
Prev close
₹107.47
Day
−0.63%
Price performance
1D
−0.63%
1W
+1.93%
1M
+21.75%
3M
+34.89%
6M
+63.29%
1Y
+28.83%
YTD
+45.79%
Financials
Revenue, profit & margin
P/E ratio
22.3×
BALPHARMA is 35% below the sector median of 34.6×
BALPHARMA22.3×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.39 | 92.54 | 81.66 | 94.63 | 74.36 | 73.69 | 73.15 | 81.88 | 65.87 | 74.02 | 87.69 | 84.08 | 88.62 | |
| Expenses | 63.95 | 84.84 | 73.87 | 85.03 | 67.89 | 66.00 | 65.40 | 74.24 | 59.81 | 68.29 | 78.15 | 73.50 | 80.67 | |
| Operating Profit | 6.44 | 7.70 | 7.79 | 9.60 | 6.47 | 7.69 | 7.75 | 7.64 | 6.06 | 5.73 | 9.54 | 10.58 | 7.95 | |
| OPM % | 9.15% | 8.32% | 9.54% | 10.14% | 8.70% | 10.44% | 10.59% | 9.33% | 9.20% | 7.74% | 10.88% | 12.58% | 8.97% | |
| Other Income | 0.16 | 0.14 | 0.10 | 2.45 | 0.82 | -0.20 | 0.51 | 1.08 | 0.72 | 1.12 | 0.33 | -0.24 | 0.44 | |
| Interest | 3.64 | 3.82 | 3.66 | 4.14 | 4.24 | 3.65 | 5.01 | 3.95 | 4.05 | 3.86 | 4.85 | 4.06 | 4.47 | |
| Depreciation | 2.53 | 2.42 | 2.96 | 2.16 | 2.43 | 2.48 | 2.69 | 2.18 | 2.52 | 2.27 | 3.23 | 3.06 | 2.78 | |
| Profit before tax | 0.43 | 1.60 | 1.27 | 5.75 | 0.62 | 1.36 | 0.56 | 2.59 | 0.21 | 0.72 | 1.79 | 3.22 | 1.14 | |
| Tax % | 79.07% | 39.38% | 33.07% | 3.65% | 58.06% | 23.53% | 7.14% | -108.88% | 0.00% | 0.00% | 0.00% | -12.11% | 0.00% | |
| Net Profit | 0.09 | 0.97 | 0.85 | 5.53 | 0.26 | 1.04 | 0.52 | 5.41 | 0.21 | 0.72 | 1.79 | 3.60 | 1.13 | |
| EPS in Rs | 0.05 | 0.61 | 0.56 | 3.46 | 0.16 | 0.65 | 0.30 | 3.41 | 0.13 | 0.45 | 1.12 | 2.25 | 0.70 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.50% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 12 Aug '26◦ |
| Earnings day | −2.50% |
| +1 day | −3.81% |
| +5 days | −4.24% |
| +15 days | −3.08% |
| +30 days | +19.02% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202650.87%Promoter
Promoters50.87%
FIIs0.15%
Public48.99%0.02
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Bal Pharma | ₹100.67 | 22.26 | 160 | 1.19% | 1 | +460.00% | 89 | +34.54% | 9.69% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts3
Credit ratings6
Announcements5
Clarification Regarding Movement In Price 10 Sep - Bal Pharma clarifies no price-sensitive event behind scrip movement on September 10, 2026.Clarification sought from Bal Pharma Ltd 10 Sep - Exchange has sought clarification from Bal Pharma Ltd on September 10, 2026 with reference to significant movement in price, in order to ensure that investors …Announcement under Regulation 30 (LODR)-Allotment 7 Sep - Bal Pharma allotted 10 lakh warrants to promoter Shailesh Siroya for ₹8.4 crore at ₹84 each.Intimation Of Record Date For Final Dividend 27 AugReg. 34 (1) Annual Report. 26 Aug - FY2025-26 annual report filed; AGM on 24 Sept 2026, dividend Rs1.20/share, director designation changes.